Is ibio a buy?

iBio has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Who owns ibio stock?

Top 10 Owners of Ibio Inc

Stockholder Stake Shares owned
The Vanguard Group, Inc. 4.72% 10,295,449
SSgA Funds Management, Inc. 2.10% 4,585,809
Geode Capital Management LLC 1.88% 4,100,969
Northern Trust Investments, Inc.(… 0.89% 1,937,986

What is the long range forecast for ibio stock?

iBio Inc quote is equal to 0.418 USD at 2022-02-07. Based on our forecasts, a long-term increase is expected, the “IBIO” stock price prognosis for 2027-01-29 is 1.637 USD. With a 5-year investment, the revenue is expected to be around +291.7%. Your current $100 investment may be up to $391.7 in 2027.

What is ibio forecast?

Ibio Inc (NYSE American:IBIO) The 2 analysts offering 12-month price forecasts for Ibio Inc have a median target of 2.25, with a high estimate of 3.00 and a low estimate of 1.50. The median estimate represents a +455.28% increase from the last price of 0.41.

Is iBio good stock?

iBio stock is recommended for those who have extensive experience in the sector of healthcare stocks. Given iBio stock’s performance, an experienced trader would be best suited for this stock due to the make-or-break nature of its performance based on its clinical trials.

How many employees does iBio have?

iBio has 51 employees.

Is ibio a buy Zacks?

Zacks’ proprietary data indicates that iBio, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the IBIO shares relative to the market in the next few months. The financial health and growth prospects of IBIO, demonstrate its potential to underperform the market.

How many employees does ibio have?

Is iBio a buy Zacks?

Where is ibio located?

Bryan, TX
Company Description: Ibio, Inc. is located in Bryan, TX, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry.

What does ibio company do?

Company Overview (NYSE MKT: IBIO), is a global leader in plant-based biologics manufacturing. iBio is leveraging its FastPharming Technologies to develop novel biopharmaceuticals for respiratory and fibrotic disease indications, among others.

What are analysts’target prices for IBio’s stock?

2 analysts have issued 12 month target prices for iBio’s shares. Their forecasts range from $2.00 to $3.00. On average, they expect iBio’s stock price to reach $2.50 in the next year. This suggests a possible upside of 64.5% from the stock’s current price. View analysts’ price targets for iBio or view top-rated stocks among Wall Street analysts.

Where can I buy IBio shares?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is iBio’s stock price today?

What is the ticker symbol for IBio?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol “IBIO.” How do I buy shares of iBio? Shares of IBIO can be purchased through any online brokerage account.

Why is IBio stock soaring higher on Friday?

Ibio (NYSEAMERICAN:IBIO) stock is soaring higher on Friday after announcing a next-generation vaccine program to treat the novel coronavirus. Source: Shutterstock This new program has it developing IBIO-202 for the prevention of coronavirus. The candidate uses antigens derived from the spike protein fused with its own LicKM booster molecule.